E3 ligase Ligand 8 is primarily utilized in targeted protein degradation strategies, particularly in the development of PROTACs (Proteolysis Targeting Chimeras). It serves as a critical component that binds to E3 ubiquitin ligases, enabling the recruitment of specific proteins for ubiquitination and subsequent degradation by the proteasome. This application is highly valuable in drug discovery and therapeutic research, especially for targeting disease-causing proteins that are traditionally considered "undruggable." Its use facilitates the selective elimination of proteins involved in cancer, neurodegenerative disorders, and other pathological conditions, offering a novel approach to modulating cellular pathways and improving treatment outcomes.